Publication:
A Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical Impact.

dc.contributor.authorNunez-Torres, Rocio
dc.contributor.authorPita, Guillermo
dc.contributor.authorPeña-Chilet, María
dc.contributor.authorLópez-López, Daniel
dc.contributor.authorZamora, Jorge
dc.contributor.authorRoldán, Gema
dc.contributor.authorHerráez, Belén
dc.contributor.authorÁlvarez, Nuria
dc.contributor.authorAlonso, María Rosario
dc.contributor.authorDopazo, Joaquín
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea
dc.date.accessioned2024-01-17T13:06:43Z
dc.date.available2024-01-17T13:06:43Z
dc.date.issued2023-04-19
dc.description.abstractThe implementation of pharmacogenetics (PGx) is a main milestones of precision medicine nowadays in order to achieve safer and more effective therapies. Nevertheless, the implementation of PGx diagnostics is extremely slow and unequal worldwide, in part due to a lack of ethnic PGx information. We analysed genetic data from 3006 Spanish individuals obtained by different high-throughput (HT) techniques. Allele frequencies were determined in our population for the main 21 actionable PGx genes associated with therapeutical changes. We found that 98% of the Spanish population harbours at least one allele associated with a therapeutical change and, thus, there would be a need for a therapeutical change in a mean of 3.31 of the 64 associated drugs. We also identified 326 putative deleterious variants that were not previously related with PGx in 18 out of the 21 main PGx genes evaluated and a total of 7122 putative deleterious variants for the 1045 PGx genes described. Additionally, we performed a comparison of the main HT diagnostic techniques, revealing that after whole genome sequencing, genotyping with the PGx HT array is the most suitable solution for PGx diagnostics. Finally, all this information was integrated in the Collaborative Spanish Variant Server to be available to and updated by the scientific community.es_ES
dc.description.peerreviewedNoes_ES
dc.description.sponsorshipCEGEN is part of the initiative IMPaCT-GENoMICA (IMP/00009) co-funded by ISCIII and the European Regional Development Fund (ERDF). Additional funding was obtained from the ISCIII Project PI18/01242, within the Health Strategic Action, which is co-funded by the European Regional Development Fund (ERDF).es_ES
dc.format.number4es_ES
dc.format.volume15es_ES
dc.identifier.citationPharmaceutics. 2023;15(4):1286.es_ES
dc.identifier.doi10.3390/pharmaceutics15041286es_ES
dc.identifier.issn1999-4923es_ES
dc.identifier.journalPharmaceuticses_ES
dc.identifier.pubmedID37111771es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17211
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/Subprograma Estatal de Generación de Conocimiento/PI18 - Proyectos de investigacion en salud (AES 2018). Modalidad proyectos en salud. (2018)/PI18/01242es_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Genotipado Humano –CEGENes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPHARMACOGENETICSes_ES
dc.subjectPHARMACOGENOMICSes_ES
dc.subjectSPNANISH POPULATIONes_ES
dc.subjectPHARMACOGENETICS CHARACTERISATIONes_ES
dc.subjectGENOTYPINGes_ES
dc.subjectSEQUENCINGes_ES
dc.subjectPOPULATIONes_ES
dc.subjectDATABASEes_ES
dc.titleA Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical Impact.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionAMes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication91f852de-9f23-4a73-b413-a8e24f66984e
relation.isAuthorOfPublication.latestForDiscovery91f852de-9f23-4a73-b413-a8e24f66984e
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationb029ca7c-43c2-46be-af9e-b34b7f455d94
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication30293a55-0e53-431f-ae8c-14ab01127be9
relation.isPublisherOfPublication.latestForDiscovery30293a55-0e53-431f-ae8c-14ab01127be9

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
comprehensiveanalysisof21_2023.pdf
Size:
2.4 MB
Format:
Adobe Portable Document Format
Description:
Artículo principal
Loading...
Thumbnail Image
Name:
comprehensiveanalysisof21_2023.webp
Size:
80.29 KB
Format:
Unknown data format
Description:
Imagen